Vitamin D 60,000 IU Dosing Protocol
For adults with vitamin D deficiency, 60,000 IU weekly is an appropriate loading dose when given for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily for standard patients or 3,000-6,000 IU daily for obese patients or those on medications affecting vitamin D metabolism. 1
Loading Phase: 60,000 IU Weekly
The 60,000 IU weekly regimen is explicitly recommended by the 2011 Endocrine Society guidelines as equivalent to 50,000 IU weekly for treating vitamin D deficiency 1. This dosing achieves target 25(OH)D levels >30 ng/mL within 8 weeks for most adults.
Duration: 8 weeks for standard adults 1
Target: Serum 25(OH)D >30 ng/mL
Recent research confirms this approach is both effective and safe. A 2024 study demonstrated that 60,000 IU weekly for 5 weeks (total 300,000 IU) effectively achieves target levels regardless of BMI, with no hypercalcemia or hypercalciuria 2. A 2019 trial showed 60,000 IU weekly increased mean vitamin D levels by 28.33 ng/mL over 10 weeks, significantly outperforming daily low-dose therapy 3.
Maintenance Phase
After completing the loading phase:
- Standard adults: 1,500-2,000 IU daily 1
- Obese patients: 3,000-6,000 IU daily 1
- Patients on anticonvulsants, glucocorticoids, ketoconazole, or AIDS medications: 3,000-6,000 IU daily 1
- Malabsorption syndromes: 3,000-6,000 IU daily 1
Alternative maintenance: 50,000 IU monthly or bimonthly has been shown effective 4
Monitoring Plan
During loading phase:
- Check serum calcium (adjusted for albumin) 1 month after starting treatment to unmask potential primary hyperparathyroidism 5
- No routine 25(OH)D monitoring needed unless symptomatic deficiency or suspected malabsorption 5
Post-loading:
- Measure 25(OH)D 1 week after completing 8-week loading regimen 1
- If target not achieved, continue loading for additional weeks or increase maintenance dose
- For obese patients or those on interfering medications, monitor 25(OH)D and adjust dosing to maintain >30 ng/mL 1
Special populations requiring serial monitoring:
- Patients with granulomatous disorders (sarcoidosis, tuberculosis, fungal infections) or lymphoma: Monitor both 25(OH)D and serum calcium due to extrarenal 1,25(OH)₂D production risk 1
- Primary hyperparathyroidism: Monitor serum calcium closely 1
Contraindications and Precautions
Absolute contraindications:
- Hypercalcemia
- Hypercalciuria (in patients with granulomatous disorders)
Relative contraindications requiring dose adjustment:
- Granulomatous disorders: Target 25(OH)D 20-30 ng/mL (not >30 ng/mL) to prevent hypercalcemia 1
- Primary hyperparathyroidism: Use with caution, monitor calcium closely 1
Drug interactions requiring awareness:
- Thiazide diuretics in hypoparathyroid patients may cause hypercalcemia 6
- Mineral oil interferes with absorption 6
Safety considerations: The therapeutic window is narrow for vitamin D-resistant rickets (12,000-500,000 IU daily range) 6, but for standard deficiency treatment, 60,000 IU weekly is well within safe limits. The 2011 guidelines note that up to 10,000 IU daily may be needed to correct deficiency in adults 1. Long-term safety data shows daily doses up to 60,000 IU for years were tolerated without hypercalcemia when 25(OH)D remained <400 ng/mL 7.
Common Pitfalls to Avoid
- Inadequate dosing for obesity: Standard doses fail in obese patients—use 2-3× higher doses 1
- Forgetting calcium supplementation: Adequate dietary calcium is necessary for clinical response 6
- Over-monitoring: Routine 25(OH)D testing during maintenance is unnecessary unless symptomatic or malabsorption suspected 5
- Missing hyperparathyroidism: Always check calcium 1 month after starting therapy 5
- Wrong target in granulomatous disease: These patients need lower targets (20-30 ng/mL, not >30 ng/mL) 1
Formulation Choice
Either vitamin D2 or D3 is acceptable 1, though D3 is generally preferred. The 60,000 IU dose typically comes as capsules, which 88.5% of patients prefer over liquid formulations 8.